BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27683821)

  • 1. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.
    Hengst J; Falk CS; Schlaphoff V; Deterding K; Manns MP; Cornberg M; Wedemeyer H
    J Infect Dis; 2016 Dec; 214(12):1965-1974. PubMed ID: 27683821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection.
    Cabral MS; Santos TPS; Santos PL; Schinoni MI; Oliveira IS; Pereira AB; Atta AM; Sousa-Atta MLB
    Cytokine; 2018 Feb; 102():200-205. PubMed ID: 28969940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.
    Carlin AF; Aristizabal P; Song Q; Wang H; Paulson MS; Stamm LM; Schooley RT; Wyles DL
    Hepatology; 2015 Oct; 62(4):1047-58. PubMed ID: 26147061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients.
    Owusu Sekyere S; Port K; Deterding K; Cornberg M; Wedemeyer H
    United European Gastroenterol J; 2021 May; 9(4):486-496. PubMed ID: 33349201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Gerber L; Estep M; Stepanova M; Escheik C; Weinstein A; Younossi ZM
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):156-64.e3. PubMed ID: 26241510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.
    Auma AWN; Shive CL; Kostadinova L; Anthony DD
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.
    Telatin V; Nicoli F; Frasson C; Menegotto N; Barbaro F; Castelli E; Erne E; Palù G; Caputo A
    Front Cell Infect Microbiol; 2019; 9():190. PubMed ID: 31259160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.
    Hou J; van Oord G; Groothuismink ZM; Claassen MA; Kreefft K; Zaaraoui-Boutahar F; van IJcken WF; Osterhaus AD; Janssen HL; Andeweg AC; de Knegt RJ; Boonstra A
    J Virol; 2014 Nov; 88(21):12254-64. PubMed ID: 25100847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series.
    Cornella SL; Stine JG; Kelly V; Caldwell SH; Shah NL
    Postgrad Med; 2015 May; 127(4):413-7. PubMed ID: 25746436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
    Gorin JB; Malone DFG; Strunz B; Carlsson T; Aleman S; Björkström NK; Falconer K; Sandberg JK
    Sci Rep; 2020 Feb; 10(1):2081. PubMed ID: 32034167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.
    Saraiva GN; do Rosário NF; Medeiros T; Leite PEC; Lacerda GS; de Andrade TG; de Azeredo EL; Ancuta P; Almeida JR; Xavier AR; Silva AA
    Mediators Inflamm; 2018; 2018():8578051. PubMed ID: 29977152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8
    Vranjkovic A; Deonarine F; Kaka S; Angel JB; Cooper CL; Crawley AM
    Front Immunol; 2019; 10():1926. PubMed ID: 31456810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of pro-inflammatory cytokines in sera of patients with hepatitis C virus infection before and after anti-viral therapy.
    Alhetheel A; Albarrag A; Shakoor Z; Alswat K; Abdo A; Al-Hamoudi W
    J Infect Dev Ctries; 2016 Oct; 10(10):1093-1098. PubMed ID: 27801372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.